Clinical and Molecular Hepatology

Article	Citations
Preface	516
An editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” by Hong et al.	504
Contemporary Trends in Extrahepatic Mortality of Chronic Liver Disease in the United States from 2014 to 2023	327
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	306
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	241
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	235
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?	170
Letter “GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study”	159
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"	120
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	115
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	110
Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurement	109
Approaches to quantifying hepatitis B virus covalently closed circular DNA	108
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	106
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	83
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis	81
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	78
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	78
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation	73
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	73
Ethanol‑Specific Stress and RAB25/GCN1 Signaling: Emerging Perspectives in Alcohol‑Associated Liver Disease	71
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease	71
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease	69
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	65
Liver organoids: Current advances and future applications for hepatology	63

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study	62
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target	61
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	60
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	60
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A	58
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	56
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	55
HCC Surveillance After Curative Treatment: A New Frontier for Abbreviated MRI Editorial on: “Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: Compari	53
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis	52
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	50
2025 KASL clinical practice guidelines for management of hepatitis C	49
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	49
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	49
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	47
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023	47
Toward hepatitis C virus elimination using artificial intelligence	47
Correspondence to the letter titled “Revisiting the Role of Non-Contrast MRI in Recurrent HCC: Bridging Diagnostic Performance and Real-World Applicability”	46
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate	46
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe	45
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	45
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs	43
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	43
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?	42
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	42
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation	41
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment	40
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	39
A decade of liver organoids: Advances in disease modeling	39
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	39
What is new in the 2024 Chinese guidelines for fatty liver disease?	39
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”	38
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease	37
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”	36
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	36
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies	35
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”	35
Plasma Lipidomic and Fungal Signatures Predict Early Mortality in Acute Liver Failure	34
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality	34
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C	34
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated	32
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	32
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study	32
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	32
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma	32
Reply to correspondence on: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes	32
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?	31
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”	31
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	31
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”	31
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression	30

Immunopathogenesis of liver fibrosis in steatotic liver disease	30
Rethinking ACLF Prognosis: Can Machine Learning Outperform Conventional Scores? Editorial on: Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Orga	30
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The	30
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma	30
Metabolic Health in Antiviral Era of Chronic Hepatitis B	29
Berberine and the gut microbiota - A novel treatment strategy for cholestatic liver disease	29
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis	28
Acute-on-chronic liver failure: Terminology, mechanisms and management	28
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	28
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences	27
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhib	27
Interaction between sarcopenia and nonalcoholic fatty liver disease	27
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	27
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma	26
Global incidence and prevalence of nonalcoholic fatty liver disease	26
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load	26
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?	26
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohe	25
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score? Editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dys	25
Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”	25
Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis	25
Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation	25
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma	24
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	24
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	24
A new Korean nomenclature for steatotic liver disease	24
Mendelian randomization does not support the effects of G CSF on decompensated liver disease	23
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	23
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	23
Gut microbiome and metabolome signatures in liver cirrhosis-related complications	23
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	23
ACSS2-mediated acetyl-CoA accumulation promotes mitophagy and tumor growth via increased H3K27ac in HBV-related HCC	23
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association	23
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	23
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	22
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	22
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	22
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	22
Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways	21
Reply to Correspondence to “Call for Preemptive Treatment of Cytomegalovirus in Patients with Cirrhosis and Acute Decompensation”	21
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	21
Letter to the editor: Clarifying Residual Drug Effects and Subgroup Outcomes in TDF-to-BSV Switch Trials	21
Stratifying Cholangiocarcinoma: Tumor Microenvironment, Molecular Drivers, and Novel Immunotherapeutic Approaches	20
KASL clinical practice guidelines for management of chronic hepatitis B	20
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	20
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	20
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	19
Screening strategy for non-alcoholic fatty liver disease	19
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	19
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	19
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	19
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	18
JCAD, a new potential therapeutic target in cholestatic liver disease	18
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis	18
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	18
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	18
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	18
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	17
Clinical implications of residual changes following HCV clearance	17
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	17
A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.	17
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues	17
Reply to correspondence on “A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on ‘Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and On	17
Evidence-based hyponatremia management in liver disease	16
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	16
Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications	16
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	16
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	16
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic	16
Harmonized ACLF Prognostication with Explainable Machine Learning Models: Traversing from Counts to Composition	16
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	16
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by	16
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	16
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	16
Plasma Exchange and Abrogation of Monocyte Activation in Wilson’s Disease	15
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”	15
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	15
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatiti	15
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	15
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization	15

Roles of X-box binding protein 1 in liver pathogenesis	14
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	14
Management of refractory ascites	14
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	14
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma	14
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	14
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and	14
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	14
Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open	14
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”	13
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]	13
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	13
Non-alcoholic fatty liver disease: Definition and subtypes	13
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults	13
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”	13
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prog	12
Congratulatory remarks	12
Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunctionassociated steatotic liver disease”: Rethinking first-line screening in MASLD: beyond the limitations of Fi	12
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	12
Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure	11
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	11
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis	11
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma developme	11
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer	11
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters	11
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. ”	11
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”	11
Acute hepatitis C virus infection: clinical update and remaining challenges	11
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults	11
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	10
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD	10
Comment on “High Steatosis-Associated Fibrosis Estimator Scores Predict Hepatocellular Carcinoma in Viral and Non-Viral Hepatitis and Metabolic Dysfunction-Associated Steatotic Liver Disease”	10
Re: “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	10
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	10
Novel Biomarkers for Alcohol-Associated Liver Disease and Their Implications Across Clinical Settings	9
Comparative Risk of Fibrosis Progression with SGLT2 vs. DPP-4 Inhibitors in MASLD and T2DM with Low-to-Intermediate Fibrosis	9
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	9
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma	9
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation	9
Hepatorenal syndrome: Current concepts and future perspectives	9
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles	9
Targeting the innate immune system in treating hepatitis B: Prospects for functional cure	9
Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular Features	9